ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3028% below fair value
$13.63+0.16 (+1.19%)
Close on Nov 17, 2026Market cap $3.05BP/E 19.5Yield –
ADMA Biologics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
ADMA Biologics's revenue for the twelve months ending Jun 30, 2026 was $512.28M, up 8.0% year over year. For fiscal 2025 it was $510.17M, up 19.6% from the year before. Over ten years it grew 53.2% a year on average. The highest annual figure on record is $510.17M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $510.17M | +19.6% |
| FY2024 | Dec 31, 2024 | $426.45M | +65.2% |
| FY2023 | Dec 31, 2023 | $258.22M | +67.6% |
| FY2022 | Dec 31, 2022 | $154.08M | +90.4% |
| FY2021 | Dec 31, 2021 | $80.94M | +91.7% |
| FY2020 | Dec 31, 2020 | $42.22M | +43.9% |
| FY2019 | Dec 31, 2019 | $29.35M | +72.8% |
| FY2018 | Dec 31, 2018 | $16.99M | -25.4% |
| FY2017 | Dec 31, 2017 | $22.76M | +113.5% |
| FY2016 | Dec 31, 2016 | $10.66M | +48.5% |
| FY2015 | Dec 31, 2015 | $7.18M | +21.3% |
| FY2014 | Dec 31, 2014 | $5.92M | +92.8% |
| FY2013 | Dec 31, 2013 | $3.07M | +174.4% |
| FY2012 | Dec 31, 2012 | $1.12M | +46.9% |
| FY2011 | Dec 31, 2011 | $761.04K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $124.40M | +2.0% |
| Q1 FY2026 | Mar 31, 2026 | $114.49M | -0.3% |
| Q4 FY2025 | Dec 31, 2025 | $139.16M | +18.4% |
| Q3 FY2025 | Sep 30, 2025 | $134.22M | +12.0% |
| Q2 FY2025 | Jun 30, 2025 | $121.98M | +13.8% |
| Q1 FY2025 | Mar 31, 2025 | $114.80M | +40.2% |
| Q4 FY2024 | Dec 31, 2024 | $117.55M | +59.1% |
| Q3 FY2024 | Sep 30, 2024 | $119.84M | +78.1% |
| Q2 FY2024 | Jun 30, 2024 | $107.19M | +78.3% |
| Q1 FY2024 | Mar 31, 2024 | $81.88M | +43.9% |
| Q4 FY2023 | Dec 31, 2023 | $73.90M | +47.9% |
| Q3 FY2023 | Sep 30, 2023 | $67.28M | +63.7% |
| Q2 FY2023 | Jun 30, 2023 | $60.12M | +77.3% |
| Q1 FY2023 | Mar 31, 2023 | $56.91M | +95.6% |
| Q4 FY2022 | Dec 31, 2022 | $49.98M | +89.4% |
| Q3 FY2022 | Sep 30, 2022 | $41.09M | +98.7% |
| Q2 FY2022 | Jun 30, 2022 | $33.91M | +90.2% |
| Q1 FY2022 | Mar 31, 2022 | $29.10M | +81.3% |
| Q4 FY2021 | Dec 31, 2021 | $26.38M | +89.0% |
| Q3 FY2021 | Sep 30, 2021 | $20.68M | +101.2% |
| Q2 FY2021 | Jun 30, 2021 | $17.83M | +129.0% |
| Q1 FY2021 | Mar 31, 2021 | $16.05M | +57.3% |
| Q4 FY2020 | Dec 31, 2020 | $13.96M | +15.9% |
| Q3 FY2020 | Sep 30, 2020 | $10.28M | +42.3% |
| Q2 FY2020 | Jun 30, 2020 | $7.79M | +18.7% |
| Q1 FY2020 | Mar 31, 2020 | $10.20M | +189.1% |
| Q4 FY2019 | Dec 31, 2019 | $12.04M | +196.7% |
| Q3 FY2019 | Sep 30, 2019 | $7.22M | +70.7% |
| Q2 FY2019 | Jun 30, 2019 | $6.56M | +40.9% |
| Q1 FY2019 | Mar 31, 2019 | $3.53M | -12.7% |
| Q4 FY2018 | Dec 31, 2018 | $4.06M | -66.2% |
| Q3 FY2018 | Sep 30, 2018 | $4.23M | -10.6% |
| Q2 FY2018 | Jun 30, 2018 | $4.66M | +37.0% |
| Q1 FY2018 | Mar 31, 2018 | $4.04M | +53.8% |
| Q4 FY2017 | Dec 31, 2017 | $12.00M | +260.7% |
| Q3 FY2017 | Sep 30, 2017 | $4.73M | +61.0% |
| Q2 FY2017 | Jun 30, 2017 | $3.40M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.63M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.33M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.94M | – |
See a number that looks wrong?